Terns Pharmaceuticals, Inc.
Small-molecule drug candidates for oncology and obesity
- Sector
- Biotech
- Headquarters
- FOSTER CITY, CA
- Founded
- 2020
- Latest Form D
- $97.7M, Jan 2021
- Total capital
- $97.7M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $97.7M
- 1 Form D · last Jan 2021
- 70 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 13
- 27 pending · first 2024
- Rank in peer group#131 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$97.7M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#131 · top 9%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Bryan YoonExecutive OfficerNamed in SEC Form D filings
- Carl Gordon, Ph.D.DirectorNamed in SEC Form D filings
- David FellowsDirectorNamed in SEC Form D filings
- Elise WangDirectorNamed in SEC Form D filings
- Hongbo Lu, Ph.D.DirectorNamed in SEC Form D filings
- Jeffrey KindlerDirectorNamed in SEC Form D filings
Show all 11 people
- Jill QuigleyDirectorNamed in SEC Form D filings
- Mark Vignola, Ph.D.Executive OfficerNamed in SEC Form D filings
- Senthil SundaramDirector, Executive OfficerNamed in SEC Form D filings
- Weidong Zhong, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
- Yi Shi, Ph.D.DirectorNamed in SEC Form D filings
What it has protected
USPTO · 13 granted of 40- PendingThyroid Hormone Receptor Beta Agonist CompoundsUSPTOApplication 19426869
- GrantedThyroid Hormone Receptor Beta Agonist CompoundsUSPTOUS 12,528,791
- PendingCompounds As GLP-1R AgonistsUSPTOApplication 19242909
Show all 40 patent records
- Thyroid Hormone Receptor Beta Agonist CompoundsAug 6, 2026 · Application 19426869Pending
- Thyroid Hormone Receptor Beta Agonist CompoundsJan 20, 2026 · US 12,528,791Granted
- Compounds As GLP-1R AgonistsJan 15, 2026 · Application 19242909Pending
- Compounds As GLP-1R AgonistsJan 13, 2026 · US 12,522,596Granted
- Compounds As GLP-1R AgonistsDec 2, 2025 · US 12,486,261Granted
- COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOFDec 2, 2025 · US 12,485,118Granted
- (R)-N-(4-(CHLORODIFLUOROMETHOXY)PHENYL)-2-(DIFLUOROMETHYL)-1-(1-HYDROXYPROPAN-2-YL)-7-(PYRIMIDIN-5-YL)-1H-BENZO[D]IMIDAZOLE-5-CARBOXAMIDE, Or A Pharmaceutically Acceptable Salt Or Tautomer Thereof, For Treating Certain LeukemiasOct 28, 2025 · US 12,454,524Granted
- Compounds As GLP-1R AgonistsSep 11, 2025 · Application 18956385Pending
- Compounds As GLP-1R AgonistsSep 9, 2025 · US 12,410,163Granted
- Compounds For Treating Certain LeukemiasSep 4, 2025 · Application 19041557Pending
- Thyroid Hormone Receptor Beta Agonist CompoundsAug 26, 2025 · US 12,398,127Granted
- Compounds As GLP-1R AgonistsAug 5, 2025 · US 12,378,237Granted
- Compounds As GLP-1R AgonistsAug 5, 2025 · US 12,378,236Granted
- Compounds As GLP-1R AgonistsAug 5, 2025 · US 12,378,238Granted
- Compounds As GLP-1R AgonistsAug 5, 2025 · US 12,378,239Granted
- Treating Liver Disorders With An Ssao InhibitorMar 27, 2025 · Application 18976460Pending
- Combinations For The Treatment Of CancerMar 20, 2025 · Application 18820700Pending
- Substituted Benzamides As Intermediates In The Synthesis Of Inhibitors Of Tyrosine Kinase Enzymatic ActivityMar 4, 2025 · US 12,240,835Granted
- COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOFDec 5, 2024 · Application 18629151Pending
- Compounds As GLP-1R AgonistsNov 7, 2024 · Application 18622057Pending
- Polymorphic Forms And Salts Of A GLP-1R AgonistOct 31, 2024 · Application 18619638Pending
- Combination Treatment Of Liver DisordersSep 26, 2024 · Application 18732162Pending
- TREATMENT OF LIVER DISORDERS WITH A THR-ß AGONISTSep 5, 2024 · Application 18651843Pending
- Compounds As GLP-1R AgonistsJul 2, 2024 · US 12,024,507Granted
- Compounds And Methods For Modulating FxrApr 11, 2024 · Application 18259888Pending
- Thyroid Hormone Receptor Beta Agonist CompoundsFeb 22, 2024 · Application 18548650Pending
- Combination Treatment Of Liver DisordersJan 4, 2024 · Application 18157216Pending
- Compounds As GLP-1R AgonistsOct 12, 2023 · Application 18042443Pending
- Combination Treatment Of Liver DisordersAug 3, 2023 · Application 17985738Pending
- Treating Liver Disorders With An Ssao InhibitorJun 15, 2023 · Application 17985740Pending
- Compounds As GLP-1R AgonistsMay 18, 2023 · Application 17954047Pending
- Treatment Of Respiratory DisordersApr 27, 2023 · Application 17914163Pending
- Treating Liver DisordersDec 8, 2022 · Application 17775242Pending
- Compounds For Inhibiting FGFR4Nov 17, 2022 · Application 17621203Pending
- Thyroid Hormone Receptor Beta Agonist CompoundsNov 3, 2022 · Application 17855672Pending
- Solid Dispersion Formulations Of An Fxr AgonistMar 31, 2022 · Application 17447397Pending
- Compounds As GLP-1R AgonistsMar 24, 2022 · Application 17445588Pending
- Combination Treatment Of Liver DisordersDec 9, 2021 · Application 17318997Pending
- Combination Treatment Of Liver DisordersDec 9, 2021 · Application 17318994Pending
- Treating Liver DisordersAug 12, 2021 · Application 17271554Pending
Related companies, and why
- DTx Pharma, Inc.Similar federal contract value in Biotech · null in contracts
- FORE US Bio Inc.Similar federal contract value in Biotech · null in contracts
- Inflammasome Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Stoke TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Eledon Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- VBI Vaccines Inc/BCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .